J&J is forced to suspend recruitment in PhI diabetes study, raising questions about another Hanmi drug
J&J has run into a problem with a Phase I diabetes drug — JNJ-64565111 — in-licensed from South Korea’s Hanmi. The investigators on the study reported on clinicaltrials.gov that the trial has suspended patient recruitment, and a spokesperson for J&J tells me that the delay was due to “a manufacturing-related delay.”
“Our partnership with Hanmi remains strong regarding this drug candidate and we look forward to restarting the study,” she added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.